Digital Therapeutic Device for Improving Nicotine-Use Disorders

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E07] Innerwave Inc. is a software technology company that has grown through extensive experience in providing IT services both for public institutions and major corporations. Through continuous research and development, the company has expanded into the digital healthcare sector ― focusing on AI-based diagnostic support, treatment, and monitoring solutions, as well as AI healthcare platforms. Leveraging its expertise, Innerwave has concentrated on digital medical device development and related services.
Recently, Innerwave received regulatory approval from the Ministry of Food and Drug Safety (MFDS) in Korea for its digital therapeutic device for nicotine-use disorders, under the brand name of Dr. JinNicojini. This product is a mobile app–based digital therapy prescribed to patients after being diagnosed by psychiatric or family medicine specialists. It is structured as an eight-week program grounded in Cognitive Behavioral Therapy (CBT), combining coping strategies for nicotine cravings with motivational-enhancement training to support patient self-management in daily life.

Dr. JinNicojini is a product developed to apply cutting-edge technology through innovative medical device approval ― and it has secured content differentiation based on personalized features. The app delivers personalized content through a stepwise eight-week treatment protocol designed to facilitate behavioral change. By collecting and analyzing digital patient data, it supports adherence monitoring and sustained engagement throughout the treatment process. It is significant in that it is a digital therapeutic device that has obtained regulatory approval in Korea, with the goal of improving people’s nicotine-use disorders.
Building on its experience in developing disease-management applications and patient-management platforms for high-level general hospitals, Innerwave plans to expand its domestic clinical references following commercialization. By promoting the adoption of its innovative medical technology in healthcare institutions, the company aims to accumulate real-world clinical cases and strengthen synergies with its broader AI healthcare platform business.
For its overseas expansion strategy, Innerwave has set the German Digital Health Application (DiGA) market as its primary target. To this end, it is preparing to obtain CE MDR certification, as it believes Germany is a market where the regulatory integration of digital therapeutic devices can occur relatively quickly compared to other countries. After securing sufficient domestic references, we plan to pursue a phased expansion into the European and Southeast Asian markets.
Innerwave plans to expand its portfolio of disease-specific digital therapeutic devices based on its digital medical-device development service capabilities and AI-based platform technology.
Starting with Dr. JinNicojini Genie, the company intends to advance its technological competitiveness and business model in the field of digital therapy, and accelerate its entry into the global digital healthcare market.
Innerwave has obtained regulatory approval for software medical devices, achieving development milestones in digital medical devices, mobile health, and AI disease prediction systems—backed by AI-based development infrastructure and clinical data from medical institutions. “We are committed to driving global digital biohealth innovation through our comprehensive one-stop integrated service utilizing medical platforms, AI, and Big Data Cloud technologies,” remarked the company’s CEO.

korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

Digital Therapeutics

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E06] Founded in 2016 as a spin-off from Samsung Electronics, WELT specializes in digital therapeutics, developing digital-healthcare solutions that combine medical expertise with advanced IT technologies based upon the concept of ‘Wellness Technology.’ The company adheres to the core principle of developing clinically validated software medical devices and has expanded its business based on products that have demonstrated safety and efficacy through regulatory approval.
WELT has developed digital therapeutics for insomnia and eating disorders, and is advancing an ‘AI Combo Drug’ strategy that integrates digital treatment with conventional pharmaceutical therapies. By leveraging AI to analyze patient data, the company aims to optimize medication timing and manage treatment adherence, embedding digital technology throughout the entire patient-care journey.
In 2023, WELT obtained approval from Korea’s Ministry of Food and Drug Safety (MFDS) for its insomnia treatment, digital therapeutic SleepQ, establishing a foundation for commercialization in Korea. The company has since collaborated with pharmaceutical firm Handok to expand prescriptions and distribution across domestic medical institutions, promoting a new treatment approach that combines digital therapeutics with conventional medication.

Mobile-based Digital Therapeutic Treatment
SleepQ is a mobile-based digital therapeutic treatment that delivers Cognitive Behavioral Therapy for Insomnia (CBT-I), traditionally administered in person at hospitals. Designed as a six-week treatment program prescribed by medical professionals, SleepQ analyzes patients’ sleep diaries and behavioral data to provide personalized treatment plans.
The platform integrates core CBT-I components such as sleep restriction, stimulus control, cognitive restructuring, relaxation therapy, and sleep-hygiene education. Through a connected system comprising a patient app and a clinician dashboard, healthcare providers can monitor and manage the treatment process efficiently.

Clinical trial results have demonstrated its effectiveness. After seven weeks of treatment, patients using SleepQ showed an average 15.14% improvement in sleep efficiency and a reduction of over 55% in sleep onset latency, confirming meaningful improvements in sleep outcomes.
WELT recently also showcased DrugOS, its AI-powered drug optimization platform. DrugOS analyzes patients’ physiological and behavioral data in order to recommend optimal medication timing and dosage adjustments tailored to changes in the patient’s condition.
DrugOS implements a ‘Just-in-Time’ medication-management model by identifying disease progression patterns and optimizing medication schedules accordingly. An AI agent continuously interacts with patients to collect additional data, refining treatment strategies over time. This approach enables pharmaceutical companies to enhance therapeutic outcomes by integrating digital technology with existing drugs, without altering the drugs themselves.
In recognition of its technological innovation, WELT received a CES Innovation Awards 2026 honor, drawing global attention in the digital healthcare sector.
WELT is actively expanding into global markets. In Europe, the company has established a local subsidiary in Germany, and is conducting clinical trials for adult insomnia patients in collaboration with Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals. WELT has also secured CE certification and ISO 27001 certification, thereby reinforcing its data security and medical device quality-management systems.

In the United States, WELT is expanding its partnerships with global pharmaceutical companies through board-level engagement with the American Telemedicine Association (ATA) and is strengthening its digital healthcare ecosystem through joint research with Oura Health.
In the Middle East, the company is exploring market entry opportunities through discussions with regulatory authorities in the UAE and engaging potential partners at global exhibitions such as WHX Dubai.
Looking ahead, WELT plans to enhance SleepQ with expanded AI capabilities in SleepQ 2.0 and broaden its digital therapeutic pipeline beyond insomnia to include eating disorders, migraines, diabetes, hypertension, and other chronic conditions.

 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

AI-based Software as a Medical Device

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E05] a.cure Co., Ltd. is a digital healthcare company developing AI models that predict disease risk based on voice analysis. Established in June 2024 by a team with experience in developing Korea’s first digital therapeutic device, Somzz, the company is currently advancing by developing AI-based Software as a Medical Device (SaMD), Heart to Voice, designed to analyze the voices of heart-failure patients and high-risk groups. The solution aims to detect early warning signs, prevent emergency events, and reduce hospital readmissions.
Rather than focusing on a single product, a.cure is building a comprehensive digital medical ecosystem that spans early screening ―> diagnostic support ―> post-discharge monitoring. In the long term, the company plans to integrate traditional pharmacological treatments such as diuretics, smartphones, and mobility services to create cross-industry healthcare synergy.
a.cure is currently conducting exploratory clinical trials to further refine Heart to Voice. In the first half of this year, a.cure is advancing with the development of a 90-day prescription-based monitoring AI SaMD for heart failure patients following hospital discharge. In the second half of the year, the company aims to apply for approval through the Korean Ministry of Food and Drug Safety’s Integrated Review Program for Innovative Medical Devices.

Global expansion efforts are also underway. In the first half of the year, a.cure plans to conduct Proof-of-Concept (PoC) projects in collaboration with Medstown in India and PMK Group in Singapore, integrating Heart to Voice into local chronic-disease management platforms. In the second half of 2026, the company intends to apply for the U.S. FDA Breakthrough Devices Program (BDP).
a.cure recently unveiled its 90-day prescription monitoring AI SaMD for post-discharge heart failure patients, and is currently seeking domestic and international distribution and sales partners. The company will conduct product demonstrations and technical briefings targeting pharmaceutical companies, diagnostic firms, and digital health platform operators, while exploring strategic collaborations for overseas PoCs and commercialization.

Digital Cardiopulmonary Product
Heart to Voice is a digital medical product that analyzes approximately 10 seconds of speech using only a smartphone, without requiring additional medical equipment. The AI quantifies biological signals embedded in vocal data ― such as breathing patterns, subtle vocal tremors, and acoustic energy distribution ― closely related to cardiopulmonary function. Based on this analysis, heart-failure severity is classified into four stages ― Normal, Mild, Moderate, and Severe. Exploratory clinical trials have demonstrated predictive performance with an AUC of approximately 95%.

Because the solution is non-invasive and allows for repeated measurements, it can be used in daily life outside the hospital setting. This makes it particularly suitable for continuous monitoring after discharge and for early detection in high-risk populations, positioning it as a next-generation digital-health technology.
Globally, heart failure affects an estimated 120 million people. Approximately 24 million patients are located across five major markets: Korea, the United States, China, Japan, and Singapore. Considering patient population size, as well as digital health adoption, and healthcare accessibility, a.cure has identified the United States, Japan, China, India, Indonesia, and Singapore as key target markets. The company plans direct SaMD entry into the United States and Japan, while pursuing a phased market approach in China, India, Indonesia, and Singapore through partnerships with chronic-disease management platforms based on an “early cardiac-risk detection” wellness service model.
“We will continue enhancing the accuracy of our AI-based heart failure severity model and expanding global validation datasets to strengthen our technological credibility. Through expanded domestic and international distribution partnerships and participation in major global exhibitions ― including MEDICA 2026, SWITCH 2026, and CES 2027 (Innovation Awards application) ― we will accelerate our growth as a global leader in medical AI,” explained the company’s CEO.
 
 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With: ,

AI-Based Medical Imaging Solutions

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E04] Silla Systems Co., Ltd., founded in 2005, is a software- and AI-based medical device solution company that has expanded into the digital healthcare sector by balancing its legacy software development capabilities with advanced medical artificial-intelligence technologies.
Since 2010, Silla Systems has steadily secured technologies and patents related to medical image analysis. Based on this foundation, it has developed and is commercializing AI-powered medical imaging solutions including its Pine-DX, Walnut-DX, and AIVis-Q.
In 2024, Silla Systems obtained K-GMP certification and medical device manufacturing certification for Pine-DXC (PDC-01), establishing a compliant medical-device manufacturing and quality management system.

Silla Systems is actively conducting product validation and refining service models in collaboration with major domestic hospitals and mass-screening institutions, while gradually expanding real-world applications through research-oriented deployments.
For overseas expansion, Silla Systems has acquired ISO 13485 certification and completed Class-B medical-device registration in Vietnam, as well as medical-device distribution approval in Indonesia. Building on these milestones, the company began exporting products to a Vietnamese distributor in 2025, laying the groundwork for international market entry.

Through participation in overseas exhibitions and partner development activities, Silla Systems has signed MOUs with approximately 10 companies and is in discussions with over 30 buyers regarding potential collaboration models.

Multi-skeletal Disorder Diagnostic Support & Integrated Analysis Software
Silla Systems’ flagship product, Pine-DX, is a multi-skeletal disorder diagnostic-support and integrated-analysis software solution. The system is designed to allow modular or integrated use, depending on the needs of medical institutions and screening centers. Key functions include scoliosis analysis (Cobb’s angle and Nash-Moe analysis), bone-age assessment, ankle instability and knee ligament injury analysis, and flatfoot measurement.
The solution is designed to generate multiple analytical results from a single image, thereby enhancing diagnostic efficiency and providing clinically relevant data during the consultation process. Performance metrics include vertebral recognition accuracy measured by the mean Average Precision (mAP) of 97%, Cobb’s angle diagnostic accuracy of 95.74%, average analysis time of approximately 1.09 seconds, and mean absolute error (MAE) of 0.67 years in hand bone-age assessment.

AI-based Brain-Tumor Detection & Clinical-Decision Support System
Another core solution, Walnut-DX, is an AI-based brain-tumor detection and clinical-decision support system. It analyzes brain imaging data and provides quantitative insights to assist physicians during the diagnostic process.
Silla Systems views 2026 as a pivotal year for expanding its global footprint and has identified Vietnam as its primary overseas target market. Vietnam’s growing economy, increasing healthcare expenditure, and reliance on imported medical devices ― approximately 90% of the market ― present strong growth potential for digital healthcare solutions. Additionally, the Vietnamese government’s push to adopt digital medical technologies further strengthens market demand.
Silla Systems is currently in discussions with GH Vietnam, a local medical-device distributor, and Ibone Fiso, a medical device company operated by orthopedic specialists, regarding product-introduction and pricing strategies. These efforts are aimed at taking advantage of opportunities to supply products to local hospitals and medical institutions.
To further expand internationally, Silla Systems is pursuing regulatory approvals in additional countries including Thailand and Uzbekistan. It also aims to secure approvals for expanded product lineups by the first half of 2026.
Silla Systems is strengthening its overseas exhibition strategy, with planned participation in K-Med Expo Vietnam 2026, Indonesia HOSPITAL EXPO 2026, and Uzbekistan UZMEDEXPO 2026. Through these events, Silla Systems intends to identify local partners, conduct product demonstrations, and refine solutions in line with market needs.
 
 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

Patch-Type Wearable EEG Sleep Monitoring System

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E03] Slowave Inc. is a digital neuro-healthcare company that supports clinical decision-making through patch-type wearable electroencephalogram (EEG) sensor technology and advanced signal analysis algorithms.
Slowave has independently developed lightweight, wireless wearable EEG devices and precision signal processing technology, and continues to conduct research and development aimed at acquiring quantitative brain-signal data applicable to various neuropsychiatric conditions, including sleep disorders, delirium, and ADHD.

Slowave is further advancing its brain-signal analysis capabilities into clinically applicable diagnostic support systems. In the future, the company plans to integrate neuromodulation technologies to link analysis and treatment, expanding into precision neuro-medicine systems. Through this approach, Slowave aims to grow as a neurotech company contributing to the establishment of data-driven neurological disease-management environments.
Slowave has completed international CB certification and GMP certification for its proprietary patch-type wearable EEG hardware, securing medical device–level technical reliability and manufacturing quality-management standards. Based on this foundation, the company has commercialized its lightweight, wireless brainwave monitoring system, SLOWAVE 1.0 ― providing quantitative EEG data that clinicians can reference during patient consultations and expanding its potential for clinical application.

Slowave is also engaged in international research collaboration. Slowave is conducting joint research on EEG-based delirium analysis with the University of Michigan Medical School in the United States and is expanding its clinical research network in the U.S. market. In addition, the company plans to participate in the SLEEP 2026 conference and exhibition to be held in Baltimore, USA ― in order to validate its technology in North America and broaden global partnerships.
‘SLOWAVE 1.0’ is a Class II medical device certified by Korea’s Ministry of Food and Drug Safety (MFDS). It is a wireless, wearable EEG-based sleep monitoring system developed to complement the limitations of conventional hospital-based testing environments. By applying a patch-type electrode structure, it reduces the inconvenience of multi-channel electrode attachment and dependence on large diagnostic equipment. Once prescribed, patients can conduct sleep measurements at home or in other convenient environments, and clinicians review the analyzed results during consultations. This model enhances the traditional single-session, hospital-based testing structure by enabling repeated and continuous brainwave monitoring.

Notably, Slowave utilizes its proprietary Phase Information Analysis (PIA) algorithm to perform precise EEG signal analysis. The system aims to provide quantitative data applicable not only to sleep disorder evaluation but also to neuropsychiatric conditions such as delirium and ADHD.
Slowave has identified the United States and Japan as its primary target markets. The United States is experiencing rapid growth in digital health and neurotechnology sectors, with increasing demand for data-driven assessment of sleep disorders and neuropsychiatric conditions. Building on its research collaboration with the University of Michigan Medical School, Slowave plans to expand partnerships with major university hospitals and sleep medicine institutions for joint research and clinical applications.
Japan, a country facing rapid population aging, is also seeing increased demand for delirium and sleep disorder management. Slowave plans to secure clinical data through joint research with local university hospitals and research institutions and pursue market entry in collaboration with Japanese medical device companies.
As part of its U.S. expansion strategy, Slowave plans to participate in SLEEP 2026 and HLTH exhibitions to strengthen its network with sleep medicine researchers and clinicians, while exploring partnership opportunities with global digital health companies and investors. Through a phased global partnership strategy, the company aims to expand its presence in the digital neuro-healthcare sector.


korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

Digital Medical & Health Support Devices

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E02] VIV Health is a startup developing wearable digital healthcare devices, offering personalized health-management solutions based on biosignal processing algorithms and AI-driven analytics.
The company has advanced its core technologies in collaboration with Professor Wonseok Jang (CSO) ― formerly of Samsung Medison and Siemens Medical R&D, and currently a professor in the Department of Medical Device Industry at Yonsei University College of Medicine.
VIV Health is continuing its research and development activities at the Seoul Biohub.
On February 5, 2026, the main functions of VIV Health’s smart ring, VIV™ Ring, were officially registered under the Ministry of Food and Drug Safety’s ‘Digital Medical & Health Support Device’ framework. This marks the first case in Korea of a wearable device ― specifically in smart ring form ― being registered under this system. The registration is significant in that the device’s intended purpose and functions have been formally recognized within the institutional regulatory framework established under Korea’s Digital Medical Products Act implemented last year.
Following Samsung Electronics’ prior registration of heart rate, blood oxygen saturation, and step-counting functions within the Samsung Health app, VIV Health completed registration for the smart ring hardware itself, thereby establishing a differentiated position in the hardware-based wearable market.

The VIV™ Ring is a titanium smart ring equipped with a high-precision PPG sensor and AI-based biosignal processing algorithms, designed for 24-hour continuous monitoring. It measures and analyzes key biosignals and activity data, including heart rate, blood oxygen saturation, and step count ― while also tracking sleep, stress, heart rate variability (HRV), and exercise data in an integrated manner. Through AI analysis, the device classifies user types and provides personalized health insights.
In addition, it includes a sleep-inducing sound feature aimed at improving the sleep environment, moving beyond simple measurement toward a preventive, lifestyle improvement-focused health management model. Users can automatically measure biosignals simply by wearing the device without manual operation, and receive alerts when abnormal signs are detected. Real-time measurement functions are also available when immediate status confirmation is needed.
VIV Health is targeting both B2C and B2B markets through a scalable revenue model that combines hardware with subscription-based (SaaS) services. In Korea, the company is pursuing collaborations with healthcare platform providers, major insurance companies, and construction firms. Overseas, it is expanding OEM agreements across the United States, the Middle East, Europe, Asia, and Latin America, pursuing a diversified global market strategy rather than focusing on a single country.
VIV Health’s last participation in KIMES 2026 served as a strategic entry point for expanding into the domestic market following MFDS registration. At the exhibition, VIV Health plans to directly introduce to medical professionals and industry stakeholders the upgraded UX/UI and the smart ring’s suitability and practical applications for measuring and analyzing biosignals to support medical care and maintain or enhance health.
VIV Health highlights the fact that many chronic conditions — such as obesity, dyslipidemia, diabetes, depression, and sleep disorders — are closely related to lifestyle habits. Given that daily management is critical, 24-hour monitoring through wearable devices can establish a new standard for preventive health management.
Through its smart ring, VIV Health aims to build a data-driven health management ecosystem and grow as a company that advances preventive, lifestyle-centered care models within the wearable digital healthcare sector.

 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With: ,

Complete AI-Based Treatment Process for Musculoskeletal Diseases

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2604E01] CONNECTEVE Co., Ltd. is a medical artificial intelligence (AI) company that digitally connects the entire treatment process of musculoskeletal diseases — from diagnosis, to surgery, and post-operative management — based on AI technology.
By combining more than 100,000 high-quality proprietary medical data cases with deep learning technology, CONNECTEVE has introduced CONNEVO KOA, CONNEVO Metric, and CONNEVO Suite. Recently, the company obtained European CE MDR certification and conducted PoC projects in the Middle East, demonstrating its technological capabilities in the global market and continuing its growth trajectory.

CONNECTEVE is expanding its clinical references centered on major tertiary hospitals in Korea. To implement its solutions, the company collaborates with Seoul National University Hospital, Chung-Ang University Hospital, Wonju Medical Center, Uijeongbu St. Mary’s Hospital, and CHA Bundang Medical Center.
An increasing number of adoption and demo requests are being received from secondary-level medical institutions. Overseas, active PoC projects are underway at Burjeel Hospital in the UAE and Tzu Chi Hospital in Indonesia, while clinical collaborations are being prepared with hospitals in advanced medical markets such as the United States, Japan, Singapore, Germany, and Belgium. This global network serves as a foundation for CONNECTEVE’s AI solutions to establish themselves as internationally recognized clinical tools.
CONNECTEVE’s CONNEVO Metric automatically measures lower-limb alignment and angular data, enabling data-based comparison of pre- and post-surgical changes. CONNEVO Suite integrates these diagnostic data and provides an environment optimized for clinical workflow, improving hospital operational efficiency. A key strength is its ability to reduce variability that may arise from manual measurement processes, and enable explanations based on objective numerical values.

CONNECTEVE has designated the Middle East (UAE), Southeast Asia (Indonesia and Singapore), and Europe (Germany and Belgium) as its key target markets. In the Middle East and Southeast Asia, where medical infrastructure modernization is rapidly progressing, demand for AI solutions that improve clinical efficiency is increasing. In Europe, the company is pursuing full-scale market entry based on CE MDR certification. Building on collaboration cases with regional flagship hospitals, CONNECTEVE plans to expand partnerships with global hospital chains and distribution partners.
Moving forward, CONNECTEVE will continue participating in major medical exhibitions and academic conferences in North America, Europe, and Asia to strengthen its global network ― while implementing localization strategies tailored to each country’s medical environment. With the goal of achieving orthopedic digital transformation that connects diagnosis to surgery, the company plans to expand R&D investment and advance as a global medical AI company providing a data-driven treatment environment for both physicians and patients.
 
 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

Korea’s Exports Continue Growth

April 15, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

Recording trade surplus of $4.28 billion in March
Korea’s exports in March continued their growth trend for the sixth consecutive month despite a decrease in the number of working days, marking the tenth consecutive month of trade surplus. Semiconductor exports, the country’s largest export item, drove this growth by achieving their highest performance in 24 months.
According to the nation’s Ministry of Trade, Industry and Energy, exports in March totaled $56.56 billion, a 3.1% increase year-on-year, while imports recorded $52.28 billion, a 12.3% decrease over the same period. Consequently, the trade balance ― exports minus imports ― reached $4.28 billion, marking a streak of surpluses for the tenth consecutive month.
March exports were very positive, increasing compared to the previous year despite a 1.5 working days decrease (two-day on weekdays). Average daily exports, adjusted for working days, also recorded $2.51 billion ― a 9.9% increase from the previous year.
This trade surplus was the result of increased exports in seven of the 15 major export items. In particular, IT items (semiconductors, displays, computers, and wireless communication devices) led the nation’s exports by recording positive growth for the first time in 24 months since March 2022.

Exports of semiconductors, the largest export item, reached $11.7 billion in March ― marking the highest performance in 24 months since March 2022 ($13.1 billion) and continuing a positive trend for five consecutive months.
Exports of displays increased by 16.2% year-on-year, showing an upward trend for eight consecutive months, while computer SSDs rose by 24.5%, marking three consecutive months of growth.
Meanwhile, exports of ships surged by a massive 102.1%, continuing their positive trend for eight consecutive months. Exports of biohealth products also rose by 10.0%, marking five consecutive months of growth. In addition, exports of petroleum products also turned positive after just one month.

Movements toward Releasing Attractive New Items Continuing
Korean companies are continuously developing and launching new products. Striving to achieve their export performance goals for this year, steady efforts are being continued to strategically engage in research and development and market development.

Silla Systems’ flagship product, Pine-DX, is a multi-skeletal disorder diagnostic-support and integrated-analysis software solution. The system is designed to allow modular or integrated use, depending on the needs of medical institutions and screening centers.
Key functions include scoliosis analysis (Cobb’s angle and Nash-Moe analysis), bone-age assessment, ankle instability and knee ligament injury analysis, and flatfoot measurement.
VIV Health’s VIV™ Ring is a titanium smart ring equipped with a high-precision PPG sensor and AI-based biosignal-processing algorithms, designed for 24-hour continuous monitoring.
It measures and analyzes key biosignals and activity data, including heart rate, blood oxygen saturation, and step count ― while also tracking sleep, stress, heart-rate variability (HRV), and exercise data in an integrated manner. Through AI analysis, the device classifies user types and provides personalized health insights.

 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

Cloud-based EMR/CRM Integrated Solutions

March 18, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2603E12] TNH Co., Ltd. is a healthcare IT company that has focused on addressing the structural challenges in healthcare. Since its founding in 2008, TNH has focused on developing specialized hospital software and has consistently provided solutions tailored to the hospital operating environment, focusing on cloud-based EMR and CRM.
TNH’s unique strength lies in expanding its solutions beyond simple electronic chart provision to encompass the entire hospital workflow, encompassing reservations, treatment, consultations, payments, insurance claims, and post-mortem care, all within a single system.

Its VegasCRM is a cloud-based EMR/CRM integrated solution for dermatology, aesthetics, and plastic surgery hospitals and clinics. It is designed to integrate not only medical record management but also reservations, customer management, and insurance claims into a single system.
Real-time status boards, treatment room status boards, and a smart reservation system allow for a comprehensive overview of hospital operations. It also offers customer management through point payment and deduction functions, and pick-up desk-based treatment distribution and statistics.

The reception and consultation function using tablet charts is also a factor that increases field usability.
TNH’s HanChart Cloud is a cloud-based electronic chart solution designed specifically for the environment of Oriental medicine clinics. It supports stable hospital operations without space or equipment constraints. It also features enhanced features specific to Korean Oriental medicine clinics, such as beauty treatment image storage, CRM functionality, kiosk (HIOSK) integration for registration, and certificate issuance.

Furthermore, TNH plans to gradually introduce a solution with enhanced field usability and mobile scalability via the tablet-based medical app Mediclo. Through these initiatives, TNH aims to more organically connect EMR and CRM-based hospital operating environments and continue its role as a technology partner that reduces actual workloads in the medical field.
Currently, TNH’s solutions are used in over 3,000 hospitals and clinics nationwide, with over 15,000 medical professionals and hospital staff utilizing them in real time on average daily. TNH continues its steady growth, with revenue of KRW 5 billion in 2022, KRW 6.2 billion in 2023, KRW 8.1 billion in 2024, and KRW 9.2 billion in 2025. This success is attributed to long-term customer retention and solution reliability.

 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:

Portable Cooling Device

March 18, 2026 by Leave a Comment
https://korean-electronics.com//inquiry

[INQ. NO. 2603E13] ICE LINKER Co., Ltd., a spin-off company of Samsung C-LAB, recently introduced the world’s first portable cooling device, Ella Thera, which can cool the skin to -10°C.
Ella Thera is a portable, two-in-one device that cools to -10°C in under 100 seconds. The temperature and functionality can be freely adjusted to suit a variety of individual needs.
The company emphasizes that the skin cooler function cools the skin and relieves pain and swelling, while the warming function relaxes muscles and promotes blood circulation. The device’s unique dual function, combining cooling and heating, allows for massage and skin care anytime, anywhere.

ICE LINKER confirmed its necessity and excellence through such various events as the Tokyo Show in Japan, the Innotech Invention Competition in Taiwan, and KIMES in Korea. Ella Thera is scheduled to be marketed as a medical device starting in 2026.
ICE LINKER is currently jointly developing various products utilizing its rapid cooling technology with mid-sized and large companies, and plans to sequentially introduce a lineup of approximately 30 products to the market. Through this, the company aims to become a specialized cooling technology company that addresses heat-related discomfort.
ICE LINKER inherited Samsung Electronics’ innovative culture and was born from a recognition of its future potential. ICE LINKER is a leading company driving innovation in the global market through cutting-edge digital cooling technology. Based on its innovative solutions and technological prowess, the company delivers quality and service that exceeds customer expectations.

ICE LINKERis a company born from Samsung Electronics’ DNA of innovation, and is recognized for its future potential. It is a leading company driving innovation in the global market through cutting-edge digital cooling technology. Based on its innovative solutions and technological prowess, ICE LINKER delivers quality and service that exceeds its customers’ expectations.
ICE LINKER aims to address heat-related issues across various sectors, including people, objects, and society, utilizing its digital cooling technology. Currently, ICE LINKER has developed and mass-produced one medical product and two wellness products by using its rapid cooling technology.

 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Filed Under: Cover Story Tagged With:
Next Page»